High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$493K
$493,810
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| ELVN |
Enliven Therapeutics, Inc.
|
Director
10b5-1 Sell
|
2026-02-17 | $32,196 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
Director
10b5-1 Sell
|
2026-01-20 | $13,547 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
Director
10b5-1 Sell
|
2026-01-20 | $19,354 | S | Form 4 |
| ORIC |
Oric Pharmaceuticals, Inc.
|
Director
10b5-1 Sell
|
2026-01-16 | $42,016 | S | Form 4 |
| ORIC |
Oric Pharmaceuticals, Inc.
|
Director
10b5-1 Sell
|
2026-01-16 | $38,415 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Heyman Richard A.
• Director
10b5-1 SellΔOwn -14.6%
2026-01-09
$107,125
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Director
10b5-1 SellΔOwn -14.6%
|
2026-01-09 | $107,125 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
Director
10b5-1 Sell
|
2026-01-08 | $40,500 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Heyman Richard A.
• Director
10b5-1 SellΔOwn -21.4%
2026-01-08
$200,656
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Director
10b5-1 SellΔOwn -21.4%
|
2026-01-08 | $200,656 | S | Form 4 |
| ORIC |
Oric Pharmaceuticals, Inc.
|
Director
Other
|
2025-10-03 | $50,165 | M | Form 4 |
| ORIC |
Oric Pharmaceuticals, Inc.
|
Director
Other
|
2025-10-03 | $5,426 | M | Form 4 |